Incorporation of menin inhibitors is central to improving the outcome of difficult-to-treat leukemias.
Gustavo Rivero, MD
Advertisement
Gustavo Rivero, MD, is the director of translational research for myeloid disorders at Tampa General Hospital Cancer Institute in Florida and an associate professor of hematology/oncology.
Articles by Gustavo Rivero, MD
Dr Gustavo Rivero comments on novel treatment combinations and potential new biomarkers in patients with MDS.
Gustavo Rivero, MD, comments on the ongoing SELECT-MDS-1 trial and as well as reviewing the adverse events of the potential combination of tamibarotene with azacitidine in patients with higher-risk MDS.
Dr Gustavo Rivero reviews the treatment options for patients with newly diagnosed higher-risk MDS and discusses tamibarotene’s recent orphan drug designation.
Dr Gustavo Rivero talks about the significance of the RARA gene in patients with higher-risk MDS.
An overview of myelodysplastic syndrome (MDS) and the role of biomarker testing in patients with the disorder.
Gustavo Rivero, MD, discusses evolving therapies for patients with acute myeloid leukemia with monocytic differentiation.
Advertisement
Latest Updated Articles
Dr. Rivero on Monocytic Differentiation in AMLPublished: April 14th 2022 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5